Replicel Life Sciences Inc. is ramping up its pipeline of autologous cell therapies with intentions to file within the next several weeks its plans to initiate early stage trials of its therapies for chronic Achilles tendinosis and aging and sun-damaged skin ahead of pre-trial meetings with Shiseido Co. Ltd., the world's fourth largest cosmetics company and its partner on a developing hair regeneration therapy.